Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

Ghany MG, Marks KM, Morgan TR, Wyles DL, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Feld JJ, Gordon SC, Heller T, Jhaveri RR, Jonas MM, Kiser JJ, Linas BP, Lo Re V, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Spradling P, Terrault NA, Trooskin SB, Verna EC, Wong JB, Woolley AE, Workowski KA.

Hepatology. 2019 Dec 9. doi: 10.1002/hep.31060. [Epub ahead of print]

PMID:
31816111
2.

Challenges with stopping long-term nucleos(t)ide analogue therapy in patients with chronic hepatitis B.

Liem KS, Gehring AJ, Feld JJ, Janssen HLA.

Gastroenterology. 2019 Dec 3. pii: S0016-5085(19)41872-6. doi: 10.1053/j.gastro.2019.10.050. [Epub ahead of print] No abstract available.

PMID:
31809724
3.

Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update.

Erman A, Krahn MD, Hansen T, Wong J, Bielecki JM, Feld JJ, Wong WWL, Grootendorst P, Thein HH.

BMJ Open. 2019 Nov 11;9(11):e027491. doi: 10.1136/bmjopen-2018-027491.

4.

Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.

Cunningham EB, Hajarizadeh B, Amin J, Litwin AH, Gane E, Cooper C, Lacombe K, Hellard M, Read P, Powis J, Dalgard O, Bruneau J, Matthews GV, Feld JJ, Dillon JF, Shaw D, Bruggmann P, Conway B, Fraser C, Marks P, Dore GJ, Grebely J.

Clin Infect Dis. 2019 Nov 2. pii: ciz1089. doi: 10.1093/cid/ciz1089. [Epub ahead of print]

PMID:
31677262
5.

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.

Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Estivill Mercade G, Kho D, Petoumenos K, Marks P, Tatsch F, Gabriela Pires Dos Santos A, Gane E; SMART-C Study Group.

J Hepatol. 2019 Oct 23. pii: S0168-8278(19)30612-9. doi: 10.1016/j.jhep.2019.10.010. [Epub ahead of print]

PMID:
31655134
6.

Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis.

Lapointe-Shaw L, Austin PC, Chung H, Sander B, Kwong JC, Feld JJ.

J Hepatol. 2019 Dec;71(6):1251-1254. doi: 10.1016/j.jhep.2019.06.015. Epub 2019 Oct 22. No abstract available.

PMID:
31648817
7.

Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial.

Cypel M, Feld JJ, Galasso M, Pinto Ribeiro RV, Marks N, Kuczynski M, Kumar D, Bahinskaya I, Bagnato VS, Kurachi C, Slutsky AS, Yeung JC, Donahoe L, de Perrot M, Yasufuku K, Pierre A, Binnie M, Chaparro C, Martinu T, Chen M, Tikkanen J, Chow CW, Sidhu A, Waddell TK, Keshavjee S, Singer LG, Humar A.

Lancet Respir Med. 2019 Oct 9. pii: S2213-2600(19)30268-1. doi: 10.1016/S2213-2600(19)30268-1. [Epub ahead of print]

PMID:
31606437
8.

Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis.

Radhakrishnan K, Di Bisceglie AM, Reddy KR, Lim JK, Levitsky J, Hassan MA, Darling JM, Feld JJ, Akushevich L, Vainorius M, Nelson DR, Fried MW, Brown RS Jr, Terrault NA.

Hepatol Commun. 2019 Aug 7;3(10):1388-1399. doi: 10.1002/hep4.1412. eCollection 2019 Oct.

9.

The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach.

Erman A, Wong WWL, Feld JJ, Grootendorst P, Krahn MD.

Liver Int. 2019 Sep 11. doi: 10.1111/liv.14247. [Epub ahead of print]

PMID:
31509639
10.

Hepatitis C Core-Antigen Testing from Dried Blood Spots.

Biondi MJ, van Tilborg M, Smookler D, Heymann G, Aquino A, Perusini S, Mandel E, Kozak RA, Cherepanov V, Kowgier M, Hansen B, Goneau LW, Janssen HLA, Mazzulli T, Cloherty G, de Knegt RJ, Feld JJ.

Viruses. 2019 Sep 6;11(9). pii: E830. doi: 10.3390/v11090830.

11.

Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).

Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld JJ, Hansen BE, Janssen HLA.

Gut. 2019 Dec;68(12):2206-2213. doi: 10.1136/gutjnl-2019-318981. Epub 2019 Aug 28.

PMID:
31462554
12.

Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.

Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC.

Gastroenterology. 2019 Nov;157(5):1253-1263.e2. doi: 10.1053/j.gastro.2019.07.040. Epub 2019 Jul 30.

PMID:
31374215
13.

Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.

Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K.

Gastroenterology. 2019 Nov;157(5):1264-1278.e4. doi: 10.1053/j.gastro.2019.07.033. Epub 2019 Jul 26.

PMID:
31356807
14.

Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B.

Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, Janssen HLA, Patel K.

Hepatology. 2019 Jul 15. doi: 10.1002/hep.30857. [Epub ahead of print]

PMID:
31309589
15.

Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study.

Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J.

Clin Infect Dis. 2019 Jul 11. pii: ciz633. doi: 10.1093/cid/ciz633. [Epub ahead of print]

PMID:
31300820
16.

Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.

Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson MN, Hanna GJ, Barr E, Platt HL; C-BREEZE-2 Study Investigators.

J Viral Hepat. 2019 Sep;26(9):1127-1138. doi: 10.1111/jvh.13132. Epub 2019 Jul 11.

PMID:
31108015
17.

Hepatitis C Virus Diagnostics: The Road to Simplification.

Feld JJ.

Clin Liver Dis (Hoboken). 2018 Dec 14;12(5):125-129. doi: 10.1002/cld.760. eCollection 2018 Nov. Review. No abstract available.

18.

Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B.

Di Bisceglie AM, King WC, Lisker-Melman M, Khalili M, Belle SH, Feld JJ, Ghany MG, Janssen HLA, Lau D, Lee WM, Ling SC, Cooper S, Rosenthal P, Schwarz KB, Sterling RK, Teckman JH, Terrault N; Hepatitis B Research Network (HBRN).

J Viral Hepat. 2019 Jul;26(7):856-865. doi: 10.1111/jvh.13104. Epub 2019 May 2.

PMID:
30974509
19.

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.

Casey JL, Feld JJ, MacParland SA.

Cells. 2019 Apr 5;8(4). pii: E317. doi: 10.3390/cells8040317. Review.

20.

Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B.

Liem KS, Yim C, Ying TD, Zanjir WR, Fung S, Wong DK, Shah H, Feld JJ, Hansen BE, Janssen HLA.

Liver Int. 2019 Aug;39(8):1418-1427. doi: 10.1111/liv.14105. Epub 2019 Apr 22.

PMID:
30912219
21.

What Comes First: Treatment of Viral Hepatitis or Liver Cancer?

Feld JJ, Krassenburg LAP.

Dig Dis Sci. 2019 Apr;64(4):1041-1049. doi: 10.1007/s10620-019-05518-5. Review.

PMID:
30874985
22.

Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure.

Ajmera V, Huang H, Dao D, Feld JJ, Lau DT, Patel K, Rule JA, Daly M, Lee WM, Chung RT.

Cell Mol Gastroenterol Hepatol. 2019;7(2):477-479.e4. doi: 10.1016/j.jcmgh.2018.09.018. Epub 2018 Oct 17. No abstract available.

23.

Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.

Brahmania M, Lombardero M, Hansen BE, Terrault NA, Lok AS, Perrillo RP, Belle SH, Di Bisceglie AM, Feld JJ, Lee WM, Fried MW, Janssen HLA; Hepatitis B Research Network.

Clin Gastroenterol Hepatol. 2019 Nov;17(12):2541-2551.e2. doi: 10.1016/j.cgh.2019.02.005. Epub 2019 Feb 8.

PMID:
30743006
24.

Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion.

Galasso M, Feld JJ, Watanabe Y, Pipkin M, Summers C, Ali A, Qaqish R, Chen M, Ribeiro RVP, Ramadan K, Pires L, Bagnato VS, Kurachi C, Cherepanov V, Moonen G, Gazzalle A, Waddell TK, Liu M, Keshavjee S, Wilson BC, Humar A, Cypel M.

Nat Commun. 2019 Jan 29;10(1):481. doi: 10.1038/s41467-018-08261-z.

25.

Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.

Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND.

Gastroenterology. 2019 May;156(6):1683-1692.e1. doi: 10.1053/j.gastro.2019.01.027. Epub 2019 Jan 18.

PMID:
30660729
26.

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.

Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184. doi: 10.1016/S2468-1253(18)30270-X. Review. Erratum in: Lancet Gastroenterol Hepatol. 2019 May;4(5):e4.

27.

Resolved HBV and anti-CD20 therapy.

Hicks LK, Feld JJ.

Blood. 2019 Jan 10;133(2):104-106. doi: 10.1182/blood-2018-11-882167. No abstract available.

PMID:
30630846
28.

HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition.

Brouwer WP, Zhao Q, Hansen BE, Lau D, Khalili M, Terrault NA, Di Bisceglie AM, Perrillo RP, Fried MW, Wong D, Feld JJ, Belle SH, Janssen HLA; Hepatitis B Research Network.

Clin Gastroenterol Hepatol. 2019 Jan 7. pii: S1542-3565(19)30012-6. doi: 10.1016/j.cgh.2018.12.039. [Epub ahead of print]

PMID:
30630104
29.

Host-pathogen interactions in chronic HBV infection and transplantation of HCV-positive organs.

Feld JJ, Gehring AJ.

Nat Rev Gastroenterol Hepatol. 2019 Feb;16(2):77-78. doi: 10.1038/s41575-018-0101-y. Review. No abstract available.

PMID:
30617296
30.

Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.

Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, van der Meer AJ, Cleary SP, Janssen HLA, Chan KKW, Feld JJ.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1840-1849.e16. doi: 10.1016/j.cgh.2018.12.018. Epub 2018 Dec 20.

PMID:
30580095
31.

Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection.

Feld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network.

Hepatology. 2019 Jun;69(6):2338-2348. doi: 10.1002/hep.30417. Epub 2019 Mar 14.

PMID:
30549279
32.

Expert opinion on managing chronic HCV in patients with non-Hodgkin lymphoma and other extrahepatic malignancies.

Ferri C, Feld JJ, Bondin M, Cacoub P.

Antivir Ther. 2018;23(Suppl 2):23-33. doi: 10.3851/IMP3250. Review.

33.

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.

Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede JP, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ; D3FEAT Study Group.

Int J Drug Policy. 2018 Dec;62:94-103. doi: 10.1016/j.drugpo.2018.10.004. Epub 2018 Oct 29.

PMID:
30384028
34.

What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?

Ioannou GN, Feld JJ.

Gastroenterology. 2019 Jan;156(2):446-460.e2. doi: 10.1053/j.gastro.2018.10.033. Epub 2018 Oct 24. Review.

PMID:
30367836
35.

Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study.

Cunningham EB, Amin J, Feld JJ, Bruneau J, Dalgard O, Powis J, Hellard M, Cooper C, Read P, Conway B, Dunlop AJ, Norton B, Litwin AH, Hajarizadeh B, Thurnheer MC, Dillon JF, Weltman M, Shaw D, Bruggmann P, Gane E, Fraser C, Marks P, Applegate TL, Quiene S, Siriragavan S, Matthews GV, Dore GJ, Grebely J; SIMPLIFY study group.

Int J Drug Policy. 2018 Dec;62:14-23. doi: 10.1016/j.drugpo.2018.08.013. Epub 2018 Oct 22.

PMID:
30352330
36.

HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.

van Tilborg M, Al Marzooqi SH, Wong WWL, Maan R, Vermehren J, Maasoumy B, Mazzulli T, Bolotin S, Garber G, Guerra F, Flud CR, Kowgier M, Janssen HL, de Knegt RJ, Pawlotsky JM, Cloherty GA, Duarte-Rojo A, Sarrazin C, Wedemeyer H, Feld JJ.

Lancet Gastroenterol Hepatol. 2018 Dec;3(12):856-864. doi: 10.1016/S2468-1253(18)30271-1. Epub 2018 Sep 28.

PMID:
30274834
37.

Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study.

Lapointe-Shaw L, Georgie F, Carlone D, Cerocchi O, Chung H, Dewit Y, Feld JJ, Holder L, Kwong JC, Sander B, Flemming JA.

PLoS One. 2018 Aug 22;13(8):e0201120. doi: 10.1371/journal.pone.0201120. eCollection 2018.

38.

The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis.

Jhaveri KS, Hosseini-Nik H, Sadoughi N, Janssen H, Feld JJ, Fischer S, Menezes R, Cheung AC.

Eur Radiol. 2019 Feb;29(2):1039-1047. doi: 10.1007/s00330-018-5619-4. Epub 2018 Jul 26.

PMID:
30051141
39.

IL-15 and IFN-γ signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling.

Vahedi F, Lee AJ, Collins SE, Chew MV, Lusty E, Chen B, Dubey A, Richards CD, Feld JJ, Russell RS, Mossman KL, Ashkar AA.

Cytokine. 2019 Dec;124:154439. doi: 10.1016/j.cyto.2018.06.006. Epub 2018 Jun 19.

PMID:
29908921
40.

Tenofovir to Prevent Perinatal Transmission of Hepatitis B.

Terrault NA, Feld JJ, Lok ASF.

N Engl J Med. 2018 Jun 14;378(24):2348-9. doi: 10.1056/NEJMc1805396. No abstract available.

PMID:
29900725
41.

The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.

Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver.

CMAJ. 2018 Jun 4;190(22):E677-E687. doi: 10.1503/cmaj.170453. No abstract available.

42.

Approaches for simplified HCV diagnostic algorithms.

Fourati S, Feld JJ, Chevaliez S, Luhmann N.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25058. doi: 10.1002/jia2.25058. Review.

43.

Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B.

Khalili M, Shuhart MC, Lombardero M, Feld JJ, Kleiner DE, Chung RT, Terrault NA, Lisker-Melman M, Sanyal A, Lok AS; Hepatitis B Research Network (HBRN); Harvard Consortium.

Diabetes Care. 2018 Jun;41(6):1251-1259. doi: 10.2337/dc18-0040. Epub 2018 Mar 29.

44.

Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies.

Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N, Stamm LM, Hyland RH, McNally J, Brainard DM, Jacobson I, Zeuzem S, Bourlière M, Foster G, Afdhal N, Dore GJ.

Open Forum Infect Dis. 2018 Feb 9;5(2):ofy001. doi: 10.1093/ofid/ofy001. eCollection 2018 Feb.

45.

Hepatitis B Reactivation With Hepatitis C Treatment: Bringing Some Clarity to the Black Box.

Ma AT, Feld JJ.

Gastroenterology. 2018 Mar;154(4):795-798. doi: 10.1053/j.gastro.2018.02.005. Epub 2018 Feb 6. No abstract available.

PMID:
29425929
46.

Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review.

Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe AYM, Miller V, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Matthews GV, Wang GP, Pawlotsky JM, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL.

Hepatol Commun. 2017 May 22;1(5):379-390. doi: 10.1002/hep4.1050. eCollection 2017 Jul. Review.

47.

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.

Feld JJ, Bernstein DE, Younes Z, Vlierberghe HV, Larsen L, Tatsch F, Ferenci P.

Liver Int. 2018 Sep;38(9):1571-1575. doi: 10.1111/liv.13708. Epub 2018 Mar 14.

48.

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.

Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ.

N Engl J Med. 2018 Jan 25;378(4):354-369. doi: 10.1056/NEJMoa1702417.

49.

Population-based estimate of hepatitis C virus prevalence in Ontario, Canada.

Bolotin S, Feld JJ, Garber G, Wong WWL, Guerra FM, Mazzulli T.

PLoS One. 2018 Jan 23;13(1):e0191184. doi: 10.1371/journal.pone.0191184. eCollection 2018.

50.

Extending a Helping Hand: Addressing Hepatitis C in Economic Migrants and Refugees.

Feld JJ.

Ann Hepatol. 2018 January-February;17(1):8-10. doi: 10.5604/01.3001.0010.7529. No abstract available.

Supplemental Content

Support Center